With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden ...

Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML). In a study involving patients with CML in high-income countries, approximately half the patients who ...

Birth Weight and Risk of Childhood ALL This study confirms a previously reported association between high birth weight and the risk of developing childhood acute lymphoblastic leukemia. How might this ...

In the past 25 years — from 2000 to 2024 — we have witnessed a revolution in the management, treatment, and outcome of what used to be the most lethal hematologic cancer: Philadelphia ...

T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive form of blood cancer that can occur in both children and adults. It is characterized by failures in the maturation of T-lymphocytes, ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

(A) The levels of the METTL3 protein in MV4.11, MOLM13, and NB4 cells treated with ZW27941 for 24 h detected by Western blot. METTL3 band intensity was normalized against ACTIN in each sample and DC50 ...

Leukemia symptoms include fatigue, weakness, chest pain, shortness of breath, bleeding, bruising, and increased infection risk due to altered blood cell counts. Recent leukemia treatment advancements ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Erratum: BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203 The article by Sharman et al entitled “Phase III Trial of ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After navigating unexpected ...